Mediterranean Diet and Metabolic Outcomes in NAFLD/MASLD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction associated steatotic liver disease (MASLD), is the most prevalent chronic liver disorder worldwide and is strongly associated with obesity, insulin resistance, and cardiometabolic risk. The Mediterranean diet (MD) has been proposed as a therapeutic strategy for improving metabolic and hepatic outcomes.
Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction associated steatotic liver disease (MASLD), is the most prevalent chronic liver disorder worldwide and is strongly associated with obesity, insulin resistance, and cardiometabolic risk. The Mediterranean diet (MD) has been proposed as a therapeutic strategy for improving metabolic and hepatic outcomes.
What the study was
- Study design
- Randomized Controlled Trial (inferred)
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Clin Nutr ESPEN
Why it surfaced
Matched watchlist topic 'Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk'. Study design: Randomized Controlled Trial (inferred). Score: 8/10 (N:1, R:3, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.